Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05655520 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
NCT05655520: Clinical Trial Phase 3 study, sponsored by Supernus Pharmaceuticals.
NCT05655520 is a Phase 3 study that was terminated before completion, run by Supernus Pharmaceuticals. The registered enrollment target is 153 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05655520, a Phase 3 study, was terminated before completion, sponsored by Supernus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
Primary Outcome
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is d
Interventions
- DRUG SAGE-718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2025-01-20 |
| Phase | Phase 3 |
Why NCT05655520 stopped before completion
NCT05655520 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which SAGE-718 is the first listed.
NCT05655520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05655520 about?
NCT05655520 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease". The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
What is the current status of trial NCT05655520?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2022-12-14. Estimated completion is 2025-01-20.
What interventions are being tested in trial NCT05655520?
The interventions under investigation include: SAGE-718 (DRUG).
Who is sponsoring clinical trial NCT05655520?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05655520's enrollment target sits among peer trials
153 1510th of 2000 higher than 488 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI